CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM engaged DKSH to market its regional business in several Asian countries

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH have signed a strategic partnership for a regional cooperation in several countries in Asia.

With its latest acquisitions, CHEPLAPHARM has recently further extended and diversified its product portfolio. DKSH has now been appointed to actively manage and promote CHEPLAPHARM’s branded products in selected markets in Asia, for example in Thailand, Malaysia, Singapore, Myanmar, Cambodia, Hong Kong and Macau. Besides serving the patients‘ needs in these markets, it is also the target of this cooperation to boost the company‘s presence within this important region.

DKSH is the leading Market Expansion Services Group with a focus on Asia, supporting companies to grow their business in new or existing markets. Their dedicated team of experts provides a broad spectrum of integrated Market Expansion Services across the entire value chain. In order to realize and further develop our ambitious growth strategy and to benefit from DKSH’s in-depth knowledge of the local markets and their well-established distribution network across Asia which allows them to provide regional solutions by duplicating success across markets, CHEPLAPHARM has stepped into this strategic collaboration.

CHEPLAPHARM’s Management Board: "We are very impressed by and highly value DKSH’s experience and expertise in Asia and are looking forward to mutually develop and foster a close, trustful and professional partnership with our new business partners."

"We have come to know CHEPLAPHARM as a company with great potential. With the largest dedicated salesforce in Asia and an unwavering commitment to quality and compliance, we are keen to drive sales for our new partner CHEPLAPHARM," said Bijay Singh, Head, Business Unit Healthcare, DKSH.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com


Investor Relations topics

Back to top expand_less